1 completed, 1 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Daptomycin for Injection: new trials by email Literature Review of Daptomycin for Injection trials Research Report on Daptomycin for Injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029) Daptomycin for Injection - Bacteremia, Soft Tissue Infections | Phase 2 | Completed | Merck Sharp & Dohme LLC | 18 | 2018-12-06 | 2022-05-13 |
| Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia daptomycin, vancomycin - Endocarditis, Bacterial, Infective Endocarditis | Phase 2 | Terminated | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 38 | 2008-09-17 | 2018-12-24 |
Bacteremia (2) · Endocarditis (1) · Endocarditis, Bacterial (1) · Gram-Positive Bacterial Infections (1) · Infections (1) · Skin Diseases, Infectious (1) · Soft Tissue Infections (1) · Staphylococcal Infections (1)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Merck Sharp & Dohme LLC (1)
Japan (1) · United States (1)
Peter Pertel, MD (1)